



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	389335	PyriZinc BioActive
ARTG entry for	Medicine Listed	
Sponsor	FIT-BioCeuticals Limited	
Postal Address	Level 4 / 64 Kippax Street, Surry Hills, NSW, 2010 Australia	
ARTG Start Date	1/06/2022	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . PyriZinc BioActive

Product Type	Single Medicine Product	Effective Date	1/06/2022
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Maintain/support energy production
Maintain/support nerve conduction
Aid/assist/helps synthesis of neurotransmitters
Maintain/support nervous system function
Support healthy emotional/mood balance

Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible.
[Contains vitamin B6].

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Capsule, hard
--------------------	---------------



Australian Government
Department of Health
Therapeutic Goods Administration

Route of Administration Oral

Visual Identification

Active Ingredients

ascorbic acid	100 mg
Biotin	500 microgram
magnesium amino acid chelate	100 mg
Equivalent: magnesium	20 mg
manganese sulfate monohydrate	15.4 mg
Equivalent: manganese	5 mg
pyridoxal 5-phosphate monohydrate	26.8 mg
Equivalent: pyridoxine	17.1 mg
pyridoxine hydrochloride	100 mg
Equivalent: pyridoxine	82.3 mg
zinc citrate dihydrate	77.8 mg
Equivalent: zinc	25 mg

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
colloidal anhydrous silica
croscarmellose sodium
disodium edetate
gellan gum
hypromellose
magnesium stearate
microcrystalline cellulose
potable water
potassium acetate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary